Table 1.
Serum creatinine level and creatinine clearance of each treatment group in WKY rats with crescentic glomerulonephritis on day 14
| Group | Serum creatinine level (mg/dl) | Creatinine clearance (μl/min/100g rat) |
|---|---|---|
| Saline | 0·64 ± 0·19 | 368·1 ± 89·7 |
| CA (10mg/kg) | 0·58 ± 0·18 | 356·2 ± 137·5 |
| SCA (5mg/kg) | 0·49 ± 0·06 | 391·8 ± 53·2 |
| SCA (10mg/kg) | 0·46 ± 0·09 | 409·4 ± 86·4 |
| mouse IgG (2mg/kg) | 0·56 ± 0·11 | 424·0 ± 134·2 |
| ARP 2–4 (2mg/kg) | 0·63 ± 0·16 | 376·2 ± 133·5 |
| HRL2 (2mg/kg) | 0·64 ± 0·09 | 368·1 ± 89·7 |
| HRL3 (2mg/kg) | 0·58 ± 0·12 | 388·5 ± 100·2 |
| Normal control | 0·43 ± 0·05 | 484·7 ± 91·8 |
Data are mean ± SEM of 8 rats in each group. Numbers in parentheses represent the daily dose of the drug. There are no statistically significant differences.
CA, colominic acid; SCA, sulphated colominic acid; mouse IgG, used as a control for ARP 2–4; ARP 2–4, neutralizing anti-rat P-selectin mAb; HRL2, non-neutralizing anti-rat L-selectin mAb used as a control for HRL3; HRL3, neutralizing anti-rat L-selectin mAb.